Skip to content

Role of potentised remdesvir in COVID19 hospitalised patients.

Pilot study to assess the role of potentised remdesvir in COVID19 hospitalised patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/035296
Enrollment
30
Registered
2021-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: potentised remdesvir !C: potentised remdesvir 1c will be given 5ml 3 times a day for one week no control drug or comparator drug Intervention2: no comparator agent: no comparator agent

Sponsors

Bhaarath medical college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients over age of 18 years diagnosed with covid19 through RTPCR. 2. Any adults and gender willing to give written informed consent for participation. 3. Patients clinical condition mild covid19 (WHO ornidal scale 4 and below)

Exclusion criteria

Exclusion criteria: • Patients not willing. • Paediatric age group below 18yrs. • Pregnant women • Patients with pre existing renal or liver problems. • Patients with WHO ordinal scale 5 and above for covid19

Design outcomes

Primary

MeasureTime frame
To assess potentised remdesvir reduces the WHO ordinal scale by 2 in COVID19 hospitalised patients in 7,14,21 daysTimepoint: To assess potentised remdesvir reduces the WHO ordinal scale by 2 in COVID19 hospitalised patients in one week.

Secondary

MeasureTime frame
â?¢ To assess whether potentised remdesvir improve the outcome in covid19 patients.Timepoint: Baseline to 7, 14, 21 and 28 days

Countries

India

Contacts

Public ContactDr Baskaran Jegadish

Bhaarath medical college

sivajags@gmail.com7299911717

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026